🇺🇸 FDA
Patent

US 11278572

Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells

granted A61KA61K35/28A61K45/06

Quick answer

US patent 11278572 (Reducing CXCR4 expression and/or function to enhance engraftment of hematopoietic stem cells) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Mar 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K35/28, A61K45/06, A61P, A61P31/18